Related Experiment Video
Updated: Jan 14, 2026

A Porcine Model of Acute Autologous Pulmonary Embolism
Published on: September 6, 2024
Everolimus Induced Acute Fibrinous and Organizing Pneumonia (AFOP): A Rare Case Report
Theeb Osama Sulaiman1, Abdullah Arshad1, Fatima Al-Hattab2
1Pulmonology Department, Hamad General Hospital, Hamad Medical Corporation, Doha, Qatar.
Abstract:
A variety of conditions have been associated with acute fibrinous and organizing pneumonia (AFOP), including autoimmune disorders, infectious agents, posttransplantation complications, and medications. Everolimus, an oral selective inhibitor of the mammalian target of rapamycin, is commonly used to manage metastatic malignancies such as breast cancer. Here, we describe a patient with a history of advanced breast cancer who developed AFOP secondary to everolimus, with the condition improving following discontinuation of the drug and initiation of steroid therapy.
Insights
Acute fibrinous and organizing pneumonia (AFOP) can be caused by medications like everolimus. This case study shows AFOP in a breast cancer patient treated with everolimus, resolving with drug withdrawal and steroids.
Area of Science:
- Pulmonology
- Oncology
- Pharmacology
Background:
- Acute fibrinous and organizing pneumonia (AFOP) is a rare lung condition with diverse etiologies.
- Everolimus, a mTOR inhibitor, is utilized in treating metastatic breast cancer.
- Medication-induced lung injury is a recognized complication in cancer therapy.
Related Concept Videos
Acute Pyelonephritis I: Introduction
Acute Respiratory Failure-II
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
Acute Pyelonephritis II: Diagnostic Studies and Management
Pneumonia II: Pathophysiology
Acute Respiratory Failure-I
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
Acute Respiratory Failure-III

